Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | MAPK1 |
| Gene Name: | MAPK1 |
| Protein Full Name: | Mitogen-activated protein kinase 1 |
| Alias: | EC 2.7.11.24; ERK; ERK-2; ERT1; Kinase ERK2; MAP kinase 2; MAP kinase isoform p42; MAPK; MAPK 2; MAPK1; MAPK2; Mitogen-activated protein kinase; Mitogen-activated protein kinase 1; Mitogen-activated protein kinase 2; MK01; P41mapk; P42-MAPK; PRKM1; PRKM2 |
| Mass (Da): | 41390 |
| Number AA: | 360 |
| UniProt ID: | P28482 |
| Locus ID: | 5594 |
| COSMIC ID: | MAPK1 |
| Gene location on chromosome: | 22q11.22 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 20558 |
| Percent of cancer specimens with mutations: | 0.34 |
| Normal role description: | MAPK1 is a protein-serine/threonine kinase. Phosphorylates many diffrent transcription factors, such as ELK1. Acts as transcriptional repressor by binding directly to DNA. Essential for cyclin D1 induction. MAPK1 phosphoryltaes BCL2, which contributes to cell survival, the suppression of the apoptotic effect of BAD and up-regulation of the antiapoptotic protein MCL-1. Regulates accumulation of p53 during DNA damage response. Constitutively active in many human tumors, supposedly due to altered RAS, RAF, EGFR or other upstream elements. ERK/MAPK pathway was shown to promote cell motilty and tumour cell migration. |